First large, multicenter, open-label study utilizing HLA-B5701 screening for abacavir hypersensitivity in North America

A hypersensitivity reaction is associated with abacavir in approximately 2-8% of exposed patients. The frequency of the HLA-B*5701 allele varies across racial groups and significantly correlates with risk of hypersensitivity. Studies in Europe and Western Australia demonstrated that prospective scre...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 22; no. 13; pp. 1673 - 1675
Main Authors YOUNG, Benjamin, SQUIRES, Kathleen, PATEL, Parul, DEJESUS, Edwin, BELLOS, Nicholaos, BERGER, Daniel, SUTHERLAND-PHILLIPS, Denise H, QIMING LIAO, SHAEFER, Mark, WANNAMAKER, Paul
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 20.08.2008
Subjects
Adult
AIDS/HIV
Alleles
Anti-Retroviral Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Dideoxynucleosides - therapeutic use
Drug Hypersensitivity - genetics
Female
Genetic Testing - methods
HIV Infections - drug therapy
HLA-B Antigens - genetics
Human viral diseases
Humans
Infectious diseases
Male
Medical sciences
North America
Pharmacology. Drug treatments
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
North America
America
HLA-System
Purine nucleoside
Antiretroviral agent
RNA-directed DNA polymerase
Enzyme
Transferases
Multicenter study
Hypersensitivity
Enzyme inhibitor
Medical screening
Nucleotidyltransferases
Reverse transcriptase inhibitor
Abacavir
Nucleoside analog
Antiviral
Online AccessGet full text

Cover

More Information
Summary:A hypersensitivity reaction is associated with abacavir in approximately 2-8% of exposed patients. The frequency of the HLA-B*5701 allele varies across racial groups and significantly correlates with risk of hypersensitivity. Studies in Europe and Western Australia demonstrated that prospective screening can significantly reduce the rate of hypersensitivity by avoiding the use of abacavir in patients carrying the HLA-B*5701 allele. Prospective HLA-B*5701 screening in a large, racially diverse North American population resulted in less than 1% of individuals diagnosed with a suspected abacavir hypersensitivity reaction (ABC HSR) and no positive skin patch test through 30 weeks among HLA-B*5701-negative individuals.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0269-9370
1473-5571
DOI:10.1097/QAD.0b013e32830719aa